Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast

Reuters2026/08/27 13:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Akari Therapeutics participated in the Virtual Investor “Why Now” on-demand conference.
CEO Abizer Gaslightwala outlined an investment thesis tied to rising demand for differentiated ADC payload technologies.
Presentation emphasized the company’s PH1 RNA-splicing payload platform as a potential alternative to conventional ADC payloads.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816849) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast

You may also like

Crypto prices